BOULDER, Colo. , July 25, 2022 (GLOBE NEWSWIRE) — SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022. Company management will host a corresponding audio webcast beginning at 4:30 p.m. ET.
Those interested in listening to the audio webcast should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at https://investors.somalogic.com/.
About SomaLogic
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.
SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. They have neither been cleared or approved by the US Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory.
Investor Contact
Lauren Glaser
lglaser@somalogic.com
Marissa Bych
Gilmartin Group LLC
marissa@gilmartinir.com
Media Contact
Emilia Costales
720-798-5054
ecostales@somalogic.com
Strategic alliance set to strengthen supply chains for medical isotopes, industrial applications, and fusion technologies…
Xeltis is one of only seven companies to successfully pass evaluation phase of EIC Strategic…
The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate…
Emerging biotechnology is key for U.S. to remain dominant and secure future economic growth in…
Montreal, Quebec--(Newsfile Corp. - April 8, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE:…
NEW YORK & VALENCIA, Spain & CAMBRIDGE, England--(BUSINESS WIRE)--#AIinHealthcare--Quibim, the global pioneer in imaging biomarkers…